OncoSec Medical develops and uses ElectroOncology, a combination of its electroporation delivery technology and a chemotherapeutic or novel DNA-based immunotherapeutic to destroy cancerous tumors while remarkably, sparing healthy normal tissue. After the additional evaluation of their Phase I trial to treat solid tumor cancers, OncoSec discovered that a DNA plasmid encoded to produce IL-12 delivered by their electroporation technology, showed a regression of locally treated melanoma lesions as well as distant untreated lesions. Results indicated that 76% of all samples had at least 20% necrosis of the tumor, and 34% of those lesions showed 100% necrosis. In relation to the distant untreated lesions, results demonstrated that 10 (53%) of 19 patients showed at least stable disease or objective regression of the tumors. If left untreated only 0.25% of distant untreated metastatic melanoma tumors would be expected to clear on their own. In the Phase I trial, results showed that 15% of the 10 patients with distant untreated metastatic melanoma tumors demonstrated 100% necrosis. Also, analysis was done that resulted in the discovery that blood markers may exist that would allow the predictions of a specific sub-set of patients who would be more likely to respond to the DNA IL-12 treatment. Dr. Adil Daudm, Clinical Professor of Medicine at that University of California, San Francisco, who led the study, said, “These results provide significant encouragement that DNA-IL 12 delivered with electroporation may represent an important new treatment against challenging cancers such as melanoma.” These results have induced OncoSec to initiate three Phase II clinical trials in the next several months in patients with melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma.